ZURICH, Nov 14 (Reuters) - A Swiss economic affairs

official said that the pharmaceutical sector would make up a

large portion of $200 billion in promised investments in the

United States from the Swiss private sector as part of a trade

deal.

"Regarding investments, I can't say I'm talking about

specifics right now, but it's clear that a large portion is

coming from the pharmaceutical sector, or I would say life

sciences, because medtech is also planning certain investments,"

said Helene Budliger Artieda, director of the State Secretariat

for Economic Affairs, at a press conference.

(Reporting by John Revill, writing by Miranda Murray, editing

by Thomas Seythal)